Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
50.85 USD -1.15% Intraday chart for Halozyme Therapeutics, Inc. +14.81% +37.58%
Jun. 07 Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating MT
Jun. 07 HC Wainwright Raises Price Target on Halozyme Therapeutics to $65 From $50, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Halozyme Therapeutics : Investor Update
PU
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
PR
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
AQ
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
PR
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
PR
Halozyme to Participate in Upcoming Investor Conferences
PR
Halozyme Therapeutics: Q1 Earnings Snapshot
AQ
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR
Mahesh Krishnan Elected to Halozyme's Board of Directors
PR
Halozyme to Report First Quarter 2024 Financial and Operating Results
PR
Halozyme to Participate in Upcoming Investor Conferences
PR
Halozyme Therapeutics: Q4 Earnings Snapshot
AQ
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PR
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
PR
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
AQ
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR
Halozyme Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for Generalized Myasthenia Gravis
AQ
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
PR
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HALO Stock
  4. News Halozyme Therapeutics, Inc.
  5. Press Releases